Login Register Cart 0
Generic placeholder image

Protein & Peptide Letters

Editor-in-Chief

ISSN (Print): 0929-8665
ISSN (Online): 1875-5305

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Deciphering of The Effect of Chemotherapeutic Agents on Human Glutathione S-Transferase Enzyme and MCF-7 Cell Line

Author(s): Havva Aybek, Yusuf Temel*, Barzan Mirza Ahmed, Can Ali Ağca and Mehmet Çiftci

Volume 27, Issue 9, 2020

Page: [888 - 894] Pages: 7

DOI: 10.2174/0929866527666200413101017

Price: $65

Abstract

Background: Cancer is the disease that causes the most death after cardiovascular diseases all over the world these days. Breast cancer is the most common type of cancer among women and ranks the second among cancer-related deaths after lung cancer. Chemotherapeutics act by killing cancer cells, preventing their spread and slowing their growth. Recent studies focus on the effects of chemotherapeutics on cancer cells and new chemotherapy approaches that targeting enzymes that catalyze important metabolic reactions in the cell.

Objective: The aim of this study was to investigate the effects of chemotherapeutic agents, Tamoxifen and 5-FU, on MCF-7 cell line and human erythrocyte GST, an important enzyme of intracellular antioxidant metabolism.

Methods: In this study, it was investigated that the effect of chemotherapeutic agents, Tamoxifen and 5-FU, on MCF-7 breast cancer cell line and performed ROS analyzes. In addition, it was purified glutathione S-transferase (GST), one of the important enzymes of intracellular antioxidant mechanism, from human erythrocytes by using ammonium sulfate precipitation and glutathione agarose affinity chromatography, and investigated in vitro effects of chemotherapeutic agents, 5 - FU and Tamoxifen, on the activity of this enzyme for the first time.

Results: it was determined that Tamoxifen and 5-FU inhibited cellular viability and 5-FU increased intracellular levels of ROS, whereas Tamoxifen reduced intracellular levels of ROS. In addition, human erythrocyte GST enzyme with 16.2 EU/mg specific activity was purified 265.97-fold with a yield of 35% using ammonium sulfate precipitation and glutathione agarose affinity chromatography. The purity of the enzyme was checked by the SDS-PAGE method. In vitro effects of chemotherapeutics, 5-FU and Tamoxifen, on GST activity purified from human erythrocytes were investigated. The results showed that 5-FU increased the activity of GST in the concentration range of 77 to 1155 μM and that Tamoxifen increased the activity of GST in the concentration range of 0.54 to 2.70 μM.

Conclusion: In this study, the effects of tamoxifen and 5-FU chemotherapeutic agents on both MCF-7 cell line and human GST enzyme were examined together for the first time. Our study showed that chemotherapeutic agents (5-FU and Tamoxifen) inhibited cellular viability and Tamoxifen reduced intracellular levels of ROS whereas 5-FU increased intracellular levels of ROS. In addition, 5-FU and Tamoxifen were found to increase the activity of GST enzyme purified from the human erythrocyte.

Keywords: Breast Cancer, glutathione S-transferase, 5-FU, Tamoxifen, GSH, chemotherapeutic agents.

« Previous Next »
Graphical Abstract

[1]
Majumder, R.; Parida, P.; Paul, S.; Basak, P. In vitro and in silico study of Aloe vera leaf extract against human breast cancer. Nat. Prod. Res., 2020, 34(16), 2363-2366.
[http://dx.doi.org/10.1080/14786419.2018.1534848] [PMID: 30600703]
[2]
Bozorgi, A.; Khazaei, M.; Khazaei, M.R. New findings on breast cancer stem cells: A review. J. Breast Cancer, 2015, 18(4), 303-312.
[http://dx.doi.org/10.4048/jbc.2015.18.4.303] [PMID: 26770236]
[3]
Kutluk, T. Kanser konusunda genel bilgiler; TC Sağlık Bak; Kanser Savaş Daire Bşk. Türk Kanser Arş. ve Savaş Kurumu, 1996.
[4]
Shoyab, M.; McDonald, V.L.; Bradley, J.G.; Todaro, G.J. Amphiregulin: A bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc. Natl. Acad. Sci. USA, 1988, 85(17), 6528-6532.
[http://dx.doi.org/10.1073/pnas.85.17.6528] [PMID: 3413110]
[5]
Chang, M. Tamoxifen resistance in breast cancer. Biomol. Ther. (Seoul), 2012, 20(3), 256-267.
[http://dx.doi.org/10.4062/biomolther.2012.20.3.256] [PMID: 24130921]
[6]
Jordan, V.C. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br. J. Pharmacol., 2006, 147(S1)(Suppl. 1), S269-S276.
[http://dx.doi.org/10.1038/sj.bjp.0706399] [PMID: 16402113]
[7]
Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J.F.; Hoctin-Boes, G.; Houghton, J.; Locker, G.Y.; Tobias, J.S. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet, 2005, 365(9453), 60-62.
[http://dx.doi.org/10.1016/S0140-6736(04)17666-6] [PMID: 15639680]
[8]
Deveci, H.A.; Nazıroğlu, M.; Nur, G. 5-Fluorouracil-induced mitochondrial oxidative cytotoxicity and apoptosis are increased in MCF-7 human breast cancer cells by TRPV1 channel activation but not Hypericum perforatum treatment. Mol. Cell. Biochem., 2018, 439(1-2), 189-198.
[http://dx.doi.org/10.1007/s11010-017-3147-1] [PMID: 28795251]
[9]
Longley, D.B.; Harkin, D.P.; Johnston, P.G. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat. Rev. Cancer, 2003, 3(5), 330-338.
[http://dx.doi.org/10.1038/nrc1074] [PMID: 12724731]
[10]
Correia, A.; Silva, D.; Correia, A.; Vilanova, M.; Gärtner, F.; Vale, N. Study of new therapeutic strategies to combat breast cancer using drug combinations. Biomolecules, 2018, 8(4), 175.
[http://dx.doi.org/10.3390/biom8040175] [PMID: 30558247]
[11]
Saikolappan, S.; Kumar, B.; Shishodia, G.; Koul, S.; Koul, H.K. Reactive oxygen species and cancer: A complex interaction. Cancer Lett., 2019, 452, 132-143.
[http://dx.doi.org/10.1016/j.canlet.2019.03.020] [PMID: 30905813]
[12]
Wang, J.; Yi, J. Cancer cell killing via ROS: To increase or decrease, that is the question. Cancer Biol. Ther., 2008, 7(12), 1875-1884.
[http://dx.doi.org/10.4161/cbt.7.12.7067] [PMID: 18981733]
[13]
Moloney, J.N.; Cotter, T.G. ROS signalling in the biology of cancer. Semin. Cell Dev. Biol., 2018, 80, 50-64.
[http://dx.doi.org/10.1016/j.semcdb.2017.05.023] [PMID: 28587975]
[14]
Qian, Q.; Chen, W. Cao; Cao, Q Targeting reactive oxygen species in cancer via Chinese herbal medicine. Oxid. Med. Cell. Longev., 2019, 2019, 9240426.
[http://dx.doi.org/10.1155/2019/9240426]
[15]
Aggarwal, V.; Tuli, H.S.; Varol, A.; Thakral, F.; Yerer, M.B.; Sak, K.; Varol, M.; Jain, A.; Khan, M.A.; Sethi, G. Role of reactive oxygen species in cancer progression: Molecular mechanisms and recent advancements. Biomolecules, 2019, 9(11), 735.
[http://dx.doi.org/10.3390/biom9110735] [PMID: 31766246]
[16]
Pelicano, H.; Carney, D.; Huang, P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat., 2004, 7(2), 97-110.
[http://dx.doi.org/10.1016/j.drup.2004.01.004] [PMID: 15158766]
[17]
Conklin, K.A. Chemotherapy-associated oxidative stress: Impact on chemotherapeutic effectiveness. Integr. Cancer Ther., 2004, 3(4), 294-300.
[http://dx.doi.org/10.1177/1534735404270335] [PMID: 15523100]
[18]
Oakley, A. Glutathione transferases: A structural perspective. Drug Metab. Rev., 2011, 43(2), 138-151.
[http://dx.doi.org/10.3109/03602532.2011.558093] [PMID: 21428697]
[19]
Strange, R.C.; Jones, P.W.; Fryer, A.A. Glutathione S-transferase: Genetics and role in toxicology. Toxicol. Lett., 2000, 112-113, 357-363.
[http://dx.doi.org/10.1016/S0378-4274(99)00230-1] [PMID: 10720752]
[20]
Temel, Y.; Taysi, M.Ş. the effect of mercury chloride and boric acid on rat erythrocyte enzymes. Biol. Trace Elem. Res., 2019, 191(1), 177-182.
[http://dx.doi.org/10.1007/s12011-018-1601-x] [PMID: 30523573]
[21]
Klusek, J.; Głuszek, S.; Klusek, J. GST gene polymorphisms and the risk of colorectal cancer development. Contemp. Oncol. (Pozn.), 2014, 18(4), 219-221.
[http://dx.doi.org/10.5114/wo.2014.41388] [PMID: 25258576]
[22]
Singh, S. Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death. Cancer Chemother. Pharmacol., 2015, 75(1), 1-15.
[http://dx.doi.org/10.1007/s00280-014-2566-x] [PMID: 25143300]
[23]
Schilsky, R.L. Biochemical and clinical pharmacology of 5-fluorouracil. Oncology, 1998, 12(10 Suppl 7), 13-8.
[24]
Schilsky, R.L. Hecht, F.; Pessoa, C.F.; Gentile, L.B.; Rosenthal, D.; Carvalho, D.P.; Fortunato, R.S. The role of oxidative stress on breast cancer development and therapy. Tumor boil, 2016, 37, 4281-4291.
[http://dx.doi.org/10.1007/s13277-016-4873-9]
[25]
Kobayashi, M.; Yamamoto, M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid. Redox Signal., 2005, 7(3-4), 385-394.
[http://dx.doi.org/10.1089/ars.2005.7.385] [PMID: 15706085]
[26]
Yang, H.; Villani, R.M.; Wang, H.; Simpson, M.J.; Roberts, M.S.; Tang, M.; Liang, X. The role of cellular reactive oxygen species in cancer chemotherapy. J. Exp. Clin. Cancer Res., 2018, 37(1), 266.
[http://dx.doi.org/10.1186/s13046-018-0909-x] [PMID: 30382874]
[27]
Raza, M.H.; Siraj, S.; Arshad, A.; Waheed, U.; Aldakheel, F.; Alduraywish, S.; Arshad, M. ROS-modulated therapeutic approaches in cancer treatment. J. Cancer Res. Clin. Oncol., 2017, 143(9), 1789-1809.
[http://dx.doi.org/10.1007/s00432-017-2464-9] [PMID: 28647857]
[28]
Focaccetti, C.; Bruno, A.; Magnani, E.; Bartolini, D.; Principi, E.; Dallaglio, K.; Bucci, E.O.; Finzi, G.; Sessa, F.; Noonan, D.M.; Albini, A. Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS One, 2015, 10(2), e0115686.
[http://dx.doi.org/10.1371/journal.pone.0115686] [PMID: 25671635]
[29]
Hwang, J.J.; Kim, H.N.; Kim, J.; Cho, D.H.; Kim, M.J.; Kim, Y.S.; Kim, Y.; Park, S.J.; Koh, J.Y. Zinc(II) ion mediates tamoxifen-induced autophagy and cell death in MCF-7 breast cancer cell line. Biometals, 2010, 23(6), 997-1013.
[http://dx.doi.org/10.1007/s10534-010-9346-9] [PMID: 20524045]
[30]
Hassan, F.; Mohammed, G.; El-Hiti, G.A.; Alshanon, A.; Yousif, E. Cytotoxic effects of tamoxifen in breast cancer cells. J Unexplored Med Data., 2018, 3, 3.
[http://dx.doi.org/10.20517/2572-8180.2017.25]
[31]
Li, W.; Shi, X.; Xu, Y.; Wan, J.; Wei, S.; Zhu, R. Tamoxifen promotes apoptosis and inhibits invasion in estrogen positive breast cancer MCF 7 cells. Mol. Med. Rep., 2017, 16(1), 478-484.
[http://dx.doi.org/10.3892/mmr.2017.6603] [PMID: 28534964]
[32]
Di Pietro, G.; Magno, L.A.V.; Rios-Santos, F. Glutathione S-transferases: An overview in cancer research. Expert Opin. Drug Metab. Toxicol., 2010, 6(2), 153-170.
[http://dx.doi.org/10.1517/17425250903427980] [PMID: 20078251]
[33]
Sherratt, P.J.; Hayes, J.D. Glutathione S-transferases. Enzyme systems that metabolise drugs and other xenobiotics; John Wiley & Sons, Inc., 2002, pp. 319-352.
[http://dx.doi.org/10.1002/0470846305.ch9]
[34]
Caglayan, C.; Temel, Y.; Kandemir, F.M.; Yildirim, S.; Kucukler, S. Naringin protects against cyclophosphamide-induced hepatotoxicity and nephrotoxicity through modulation of oxidative stress, inflammation, apoptosis, autophagy, and DNA damage. Environ. Sci. Pollut. Res. Int., 2018, 25(21), 20968-20984.
[http://dx.doi.org/10.1007/s11356-018-2242-5] [PMID: 29766429]
[35]
Coban, T.A.; Senturk, M.; Ciftci, M.; Kufrevioglu, O.I. Effects of some metal ions on human erythrocyte glutathione reductase: An in vitro study. Protein Pept. Lett., 2007, 14(10), 1027-1030.
[http://dx.doi.org/10.2174/092986607782541060] [PMID: 18221002]
[36]
Temel, Y.; Koçyigit, U.M.; Taysı, M.Ş.; Gökalp, F.; Gürdere, M.B.; Budak, Y.; Ceylan, M.; Gülçin, İ.; Çiftci, M. Purification of glutathione S-transferase enzyme from quail liver tissue and inhibition effects of (3aR,4S,7R,7aS)-2-(4-((E)-3-(aryl)acryloyl) phenyl)-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione derivatives on the enzyme activity. J. Biochem. Mol. Toxicol., 2018, 32(3), e22034.
[http://dx.doi.org/10.1002/jbt.22034] [PMID: 29350485]

Rights & Permissions Print Cite
Article Metrics
14
© 2024 Bentham Science Publishers | Privacy Policy